Navigation Links
Acute Myeloid Leukemia Drugs Price Analysis and Strategies 2012-2016 & Forecasts to 2021 - Research and Markets
Date:3/1/2017

DUBLIN, Mar 01, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Acute Myeloid Leukemia Drugs Price Analysis and Strategies - 2016" report to their offering.

The latest research Acute Myeloid Leukemia Drugs Price Analysis and Strategies - 2016, provides drug pricing data and benchmarks in the global Acute Myeloid Leukemia market.

This research will help executives identify clinical attributes of your competitor drugs and find out how the marketed products for Acute Myeloid Leukemia are clinically and commercially positioned. It will help the reader understand the price of your competitor drugs by countries. The report will also reveal the pricing and reimbursement landscape by countries as well as identify the unmet need in global Acute Myeloid Leukemia market

The research answers the following questions:

  • What are the key drugs marketed for Acute Myeloid Leukemia and their clinical attributes? How are they positioned in the Global Acute Myeloid Leukemia market?
  • What are the unit prices and annual treatment cost for Acute Myeloid Leukemia therapies in different countries? What are the drug pricing trends and how are they expected to change in the future? How are the drug pricing and reimbursement landscape different by countries?
  • What are the unmet needs in the global Acute Myeloid Leukemia drugs market? What would be the ideal pricing strategy for a new pipeline therapy for Acute Myeloid Leukemia?

Research Scope:

  • Acute Myeloid Leukemia Treatment Options - Identify key drugs marketed and prescribed for Acute Myeloid Leukemia in the US, Germany, France, Italy, Spain, UK, Japan including trade name, molecule name, and company
  • Acute Myeloid Leukemia Drugs Attributes - Find out the safety, efficacy, and risk benefit for key drugs marketed for Acute Myeloid Leukemia
  • Market Positioning - Identify how drugs are clinically and commercially positioned in the global Acute Myeloid Leukemia market
  • Acute Myeloid Leukemia Drugs Price Analysis - Find out the annual therapy cost and unit price for key drugs marketed for Acute Myeloid Leukemia in the US, Germany, France, Italy, Spain, UK, Japan. Find out how the price advanced from 2012 and forecast to 2021
  • Pricing & Reimbursement Landscape - Find out the pricing and reimbursement landscape in the US, Germany, France, Italy, Spain, UK, Japan
  • Acute Myeloid Leukemia New Drug Pricing - Identify the effective pricing strategy for a new drug launch in the US, Germany, France, Italy, Spain, UK, Japan

Key Topics Covered:

1. Acute Myeloid Leukemia Treatment Options

2. Acute Myeloid Leukemia Drugs Clinical Attributes

3. Acute Myeloid Leukemia Drugs Market Positioning

4. Acute Myeloid Leukemia Drugs Price Analysis

5. Acute Myeloid Leukemia Drugs Price Benchmarks

6. Drug Pricing & Reimbursement Landscape

7. Acute Myeloid Leukemia Drugs Price Forecast

8. Acute Myeloid Leukemia Market Unmet Needs

9. Acute Myeloid Leukemia New Drug Pricing

For more information about this report visit http://www.researchandmarkets.com/research/z4rf2q/acute_myeloid

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com 

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/acute-myeloid-leukemia-drugs-price-analysis-and-strategies-2012-2016--forecasts-to-2021---research-and-markets-300415820.html


'/>"/>
SOURCE Research and Markets
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Novartiss Serelaxin Has the Potential to Fulfill the Most Pertinent Unmet Needs in Acute Heart Failure by Reducing the Rate of Patient Mortality and the Rate of Worsening Renal Function
2. OpportunityAnalyzer: Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2017
3. The Leukemia & Lymphoma Society and the Knight Cancer Institute Launch Groundbreaking Collaboration to Improve Outcomes for Acute Myeloid Leukemia Patients
4. Questcor To Commence Phase 2 Study of Acthar for Acute Respiratory Distress Syndrome
5. CoLucid Pharmaceuticals and ILDONG Pharmaceutical Enter into a Distribution and Supply Agreement for Lasmiditan, a Novel Agent for Acute Migraine
6. Strong Efficacy Data Prompt Charleston Laboratories to Halt Phase 3 Study of CL-108 in Patients with Moderate to Severe Acute Pain
7. U.S. Army Rangers Initiate Groundbreaking Study on Wireless Microcurrent Generating Wound Dressing for Acute Wounds
8. Systematic Review Finds Intranasal Midazolam Comparable To Intravenous Or Rectal Administration Of Diazepam For Treatment Of Acute Seizure Emergencies In Pediatric Patients
9. Polaris Group Announces Treatment of First Patient in Phase 2 Study of ADI-PEG 20 in Acute Myeloid Leukemia
10. FDA Designates MST-188 As An Orphan Drug For Treatment Of Acute Limb Ischemia
11. Revalesio Presents Update on the Development of RNS60 As A Therapeutic for Acute Heart Disease At the American Heart Association Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... SEOUL, South Korea , Oct. 4, 2017 /PRNewswire/ ... launched its next-generation CPR training aide "cprCUBE" on Kickstarter. ... of chest compression during cardiac arrests with better efficiency ... patient-mannequins. It also offers real-time feedback on efficacy of ... The crowdfunding campaign has a goal to raise ...
(Date:10/2/2017)... Oct. 2, 2017 Diplomat Pharmacy, Inc. (NYSE: ... Software and Consulting, LLC , and named its founder ... based in Tennessee , will operate ... expands EnvoyHealth,s service offerings for health care partners to ... "In an interoperable world, technology ...
(Date:10/2/2017)... Halo Labs announces the European launch of their new low volume, ... 2017 in Cambridge, U.K on October 4th. ... samples with unprecedented speed and sensitivity while using far less sample ... ... system ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 13, 2017 , ... As health professionals work to improve their approach to ... is doing more than filling out a survey; in many cases health professionals and ... in health care and research on the importance of active engagement with patients and ...
(Date:10/13/2017)... ... , ... PurhealthRX , a leading Health and Nutrition Company, is announcing ... full spectrum CBD oil will revolutionize the rapidly growing CBD market by reducing the ... incorporated into liquid products, while reducing costs to end users. , The team of ...
(Date:10/13/2017)... Calif. (PRWEB) , ... October 13, 2017 , ... Many ... dementia. However, many long-term care insurance companies have a waiver for care if the ... 90-day elimination period, when the family pays for care, is often waived, so the ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... one of the most popular and least understood books in the Holy Scriptures, Revelation. ... descriptions that have baffled scholars for centuries. Many have tossed it off as mere ...
(Date:10/13/2017)... , ... October 13, 2017 , ... “America On The ... identity. “America On The Brink” is the creation of published author, William Nowers. ... great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
Breaking Medicine News(10 mins):